The Proceedings of the 10th WFH Global Forum on Research and Treatment Products for Bleeding Disorders are now available online. The 10th WFH Global Forum—held...
Roche has announced that the U.S.A Food and Drug Administration (FDA) has approved Hemlibra (emicizumab-kxwh) for the treatment of hemophilia A with inhibitors. This approval...
The results of the SIPPET (Survey of Inhibitors in Plasma-Products Exposed Toddlers) study were published May 26, 2016 in the New England Journal of Medicine....
May, 2016 – The results of the SIPPET (Survey of Inhibitors in Plasma-Products Exposed Toddlers) study were published today in the New England Journal of...
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has completed a review of data examining the risk of inhibitors associated with...
Access to safe and effective treatment products continues to improve each year due to the tireless advocacy from the global bleeding disorders community. This strategic priority...
The World Federation of Hemophilia (WFH) has begun collecting data from the national member organizations (NMOs) for the 2014 Annual Global Survey. Each year, our...
Shipments of factor VIII manufactured as part of Project Recovery have started arriving at treatment centres around the world. These are the first deliveries in...